Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$90.87 0.64 (0.7%) as of 4:30 Tue 4/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 17.12(B)
Last Volume: 1,235,787 Avg Vol: 1,397,134
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 658,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $62,013,572
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 58
End Date 2024-01-18 2023-10-17 2023-04-18 2022-04-18

   
Records found: 1268
  Page 9 of 51  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-13 4 GD $0.00 $0 D/D 7,064 90,101     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-05-13 4 S $69.29 $179,452 D/D (2,590) 41,708     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-12 4/A D $67.68 $591,659 D/D (8,742) 102,165     -
   Wood Mark VP, Human Resources   •       –      –    2013-05-12 4 D $67.68 $152,821 D/D (2,258) 20,277     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-05-12 4 D $67.68 $55,295 D/D (817) 8,107     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-05-12 4 D $67.68 $203,108 D/D (3,001) 39,373     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-05-12 4 D $67.68 $50,895 D/D (752) 8,518     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-12 4 D $67.68 $600,525 D/D (8,873) 102,165     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-05-12 4 D $67.68 $74,177 D/D (1,096) 44,298     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-10 4 AS $67.48 $53,985 D/D (800) 111,038     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-05-09 4 AS $66.00 $53,528 D/D (811) 9,270     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-05-08 4 D $65.32 $31,288 D/D (479) 8,924     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-05-08 4 D $65.32 $108,692 D/D (1,664) 45,394     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-05-08 4 D $65.32 $31,941 D/D (489) 10,081     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-05-08 4 D $65.32 $136,388 D/D (2,088) 50,262     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-05-08 4 D $65.32 $204,517 D/D (3,131) 42,374     -
   Wood Mark VP, Human Resources   •       –      –    2013-05-08 4 D $65.32 $85,243 D/D (1,305) 22,535     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-08 4 GD $0.00 $0 D/D 1,000 111,838     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-08 4 D $65.32 $357,888 D/D (5,479) 112,838     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-08 4 AS $65.88 $65,879 D/D (1,000) 118,317     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-07 4 AS $65.87 $197,613 I/I (3,000) 13,545     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-07 4 OE $12.99 $38,970 I/I 3,000 16,545     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-03 4 AS $67.21 $537,950 I/I (8,000) 13,545     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-03 4 OE $12.99 $103,920 I/I 8,000 18,545     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-05-03 4 AS $67.00 $1,340,000 D/D (20,000) 53,155     -
  1268 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 51
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us